Testing Libevitug for chronic hepatitis D
Part of Digestive system, Infections clinical trials.
This study tests a new drug, Libevitug, for people with chronic hepatitis D (HDV). It aims to see if the drug can help control the virus and improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had hepatitis D for at least 6 months.
- Your HDV viral load is at least 500 IU/mL at screening.
- Your ALT level is above normal but less than 10 times the upper limit.
- You do not have serious liver scarring (decompensated cirrhosis) or liver cancer.
- You have not had alcohol abuse or drug addiction in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, brelovitug, against an existing one, bulevirtide, for people with chronic hepatitis delta. It aims to find a better treatment to lower the virus and protect the liver.
This trial tests an experimental medicine called ABI-6250 for people with chronic hepatitis D. The goal is to see if it is safe and can help control the infection.
This trial tests a new drug, GS-4321, for people with chronic hepatitis delta, a serious liver infection. It aims to see if the drug is safe and effective, and compares results in healthy volunteers and those with the virus.
This trial tests a new drug called Hepalatide for people with chronic hepatitis D (a liver infection). You must already have hepatitis B and be on a stable antiviral for it. The study checks if Hepalatide can safely lower HDV levels.
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
Hear when a new Chronic Hepatitis D Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.